A conference call will be held today, Wednesday, October 22, 5:00 p.m. E.D.T. DUSA Pharmaceuticals, Inc.® (NASDAQ GM: DUSA) announced today results from its Phase IIB clinical trial to compare the ...

LEVULAN KERASTICK offers patients and health care practitioners a treatment option with a well-established safety and efficacy profile that can prevent the progression of actinic keratoses into skin ...

LEVULAN KERASTICK for topical solution, 20%, plus blue light illumination using the BLU-U Blue Light Photodynamic Therapy Illuminator is used to treat minimally to moderately thick actinic keratoses ...

June 1, 2007 — The US Food and Drug Administration (FDA) has granted orphan drug designation for aminolevulinic acid HCl in combination with photodynamic therapy for the treatment of esophageal ...

Despite its possibly devastating effects, 64-year-old John Wickham loves the sun. “Even though I tried to take care of my skin there were times I didn't,” he said. For several years, Wickham has been ...

Aminolevulinic acid HCl 20%; topical soln; contains alcohol. Following the application of Levulan Kerastick topical solution, photosensitization occurs through the metabolic conversion of ...

A Sun Pharma unit on Aug. 24 agreed to pay $20.75 million to settle allegations of giving physicians misleading treatment instructions for its acne treatment Levulan Kerastick, causing insurers and ...

We are confident that Sun Pharma will build upon the solid foundation our organization has established in the United States dermatology market to further expand access to Levulan® for patients with ...

Right now, about 58 million Americans suffer from the most common form of skin pre-cancer - Actinic Kerotosis (AK). I say pre-cancer because with the right treatment, this relatively common skin ...

Acquiring the Canadian rights to LEVULAN KERASTICK (aminolevulinic acid hydrochloride) further expands the Sun Pharma Canada dermatology portfolio and reinforces the company's commitment to patient ...

Sun Pharmaceutical Industries has announced it will acquire DUSA Pharmaceuticals for approximately $230 million in cash, according to a news release (pdf). DUSA is a Wilmington, Mass-based dermatology ...